JP2023524819A5 - - Google Patents
Info
- Publication number
- JP2023524819A5 JP2023524819A5 JP2022567591A JP2022567591A JP2023524819A5 JP 2023524819 A5 JP2023524819 A5 JP 2023524819A5 JP 2022567591 A JP2022567591 A JP 2022567591A JP 2022567591 A JP2022567591 A JP 2022567591A JP 2023524819 A5 JP2023524819 A5 JP 2023524819A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063020245P | 2020-05-05 | 2020-05-05 | |
| US63/020,245 | 2020-05-05 | ||
| PCT/US2021/030930 WO2021242493A2 (en) | 2020-05-05 | 2021-05-05 | Compositions and methods for treating epilepsy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023524819A JP2023524819A (ja) | 2023-06-13 |
| JP2023524819A5 true JP2023524819A5 (enExample) | 2024-05-15 |
Family
ID=78745740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022567591A Pending JP2023524819A (ja) | 2020-05-05 | 2021-05-05 | てんかんを治療するための組成物及び方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240034775A1 (enExample) |
| EP (1) | EP4146276A4 (enExample) |
| JP (1) | JP2023524819A (enExample) |
| CN (1) | CN115996752B (enExample) |
| AU (1) | AU2021278819A1 (enExample) |
| CA (1) | CA3177879A1 (enExample) |
| MX (1) | MX2022013927A (enExample) |
| WO (1) | WO2021242493A2 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201510316UA (en) | 2013-07-09 | 2016-01-28 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
| US12486322B2 (en) * | 2021-12-13 | 2025-12-02 | Annexon, Inc. | Anti-complement factor C1q antibodies with single binding arms and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2912396T3 (es) * | 2012-11-02 | 2022-05-25 | Bioverativ Usa Inc | Anticuerpos anti-C1s del complemento y uso de los mismos |
| SG11201510316UA (en) * | 2013-07-09 | 2016-01-28 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
| PL3215527T3 (pl) * | 2014-11-05 | 2025-04-28 | Annexon, Inc. | Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie |
| JP6779876B2 (ja) * | 2014-11-19 | 2020-11-04 | ジェネンテック， インコーポレイテッド | 抗トランスフェリン受容体抗体及びその使用方法 |
| IL309260B2 (en) * | 2015-07-24 | 2025-01-01 | Gliknik Inc | Fusion proteins of human protein fragments to create ordered multimeric immunoglobulin FC preparations with enhanced complement binding |
| FI3380518T3 (fi) * | 2015-11-24 | 2026-05-29 | Annexon Inc | Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä |
| US20190161535A1 (en) * | 2016-05-09 | 2019-05-30 | Annexon, Inc. | Compositions and methods for treating spinal muscular atrophy |
| EP3487531A4 (en) * | 2016-07-19 | 2020-03-25 | Annexon, Inc. | TREATMENT OF FRONTO-TEMPORAL DEMENTIA |
| CN112867394B9 (zh) * | 2018-06-04 | 2024-12-06 | 马萨诸塞州渤健公司 | 具有降低的效应功能的抗vla-4抗体 |
| MX2021004819A (es) * | 2018-11-02 | 2021-06-08 | Annexon Inc | Composiciones y metodos para tratar lesiones cerebrales. |
| WO2020124013A1 (en) * | 2018-12-13 | 2020-06-18 | Gryphon Bio, Inc. | Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair |
-
2021
- 2021-05-05 US US17/923,456 patent/US20240034775A1/en active Pending
- 2021-05-05 WO PCT/US2021/030930 patent/WO2021242493A2/en not_active Ceased
- 2021-05-05 CN CN202180032987.3A patent/CN115996752B/zh active Active
- 2021-05-05 JP JP2022567591A patent/JP2023524819A/ja active Pending
- 2021-05-05 EP EP21813355.1A patent/EP4146276A4/en active Pending
- 2021-05-05 CA CA3177879A patent/CA3177879A1/en active Pending
- 2021-05-05 AU AU2021278819A patent/AU2021278819A1/en active Pending
- 2021-05-05 MX MX2022013927A patent/MX2022013927A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022512863A5 (enExample) | ||
| US12325745B2 (en) | Anti-DLL3 antibodies and uses thereof | |
| US20210230269A1 (en) | Immune-stimulating monoclonal antibodies against human interleukin-2 | |
| CN106456760B (zh) | 人源化的抗-Tau(pS422)抗体脑穿梭物及其应用 | |
| CA3179911A1 (en) | Compositions and methods for blood-brain barrier delivery | |
| CN113874400A (zh) | 抗Vβ17/抗CD123双特异性抗体 | |
| JP2023159380A (ja) | ＰＤ－１とＴＧＦ－ｂｅｔａを標的とした四価二重特異性抗体、その製造方法および用途 | |
| US20230088269A1 (en) | Anti-il-22r antibodies | |
| CN116888153A (zh) | 与γ-δT细胞受体结合的抗体 | |
| IL270729B2 (en) | Therapeutic anti-CD40 ligand antibodies | |
| JP2019505166A5 (enExample) | ||
| US20180208646A1 (en) | Anti-laminin4 antibodies specific for lg4-5 | |
| JP2022513050A5 (enExample) | ||
| CN108883163A (zh) | 用于癌症治疗的抗存活蛋白抗体 | |
| CN121399158A (zh) | 用于治疗多发性骨髓瘤的方法 | |
| JP2022527790A5 (enExample) | ||
| JP2024539141A5 (enExample) | ||
| JP2026513844A (ja) | 抗ｉｇｆ１ｒ抗体及びその使用 | |
| CN119486756A (zh) | 包含结合γ-δ T细胞受体的抗体的组合物 | |
| TW202519261A (zh) | 用於治療癌症之結合γ-δ T細胞受體之抗體 | |
| CA3212336A1 (en) | Methods for treating multiple myeloma | |
| WO2022123293A1 (ko) | 항 OX40L 항체, 항 OX40L 및 항 TNFα 이중 특이성 항체 및 이들의 용도 | |
| EA053202B1 (ru) | Антитела, которые связывают гамма-дельта т-клеточные рецепторы | |
| CN120035606A (zh) | 一种治疗实体瘤的方法 | |
| CN119677537A (zh) | 用于治疗狼疮性肾炎的组合物和方法 |